优化pyrazole/1,2,4-triazole作为EGFR/COX-2双抑制剂:设计,合成,抗癌潜力,亡诱导和细胞周期分析
相关实验视频
Updated: May 29, 2025

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
Nesma M Kahk1, Fatma E A Mohamed1, Marwa M Abdelhakeem1
1Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni- Suef, 62514, Egypt.
新型pyrazol-4-yl-1,2,4-triazole-3-thiol衍生物对乳腺,结肠和肺癌细胞系表现出显著的抗增殖活性. 最强效的化合物有效抑制COX-2和EGFR酶,诱导细胞亡和细胞循环停止.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症生物学 癌症生物学
背景情况:
- 癌症仍然是全球主要的死亡原因,需要开发新的治疗药物.
- 针对循环氧化酶-2 (COX-2) 和表皮生长因子受体 (EGFR) 等关键酶是癌症治疗中经过验证的策略.
- 皮拉佐洛醇支架已经成为抗癌药物发现的有前途的药剂.
研究的目的:
- 设计,合成和描述一系列新的pyrazol-4-yl-1,2,4-triazole-3-thiol衍生物.
- 评估这些化合物对人类乳腺癌 (MCF-7),结肠癌 (HT-29) 和肺癌 (A-549) 细胞系的体外抗增殖活性.
- 研究作用机制,包括酶抑制 (COX-2,EGFR) 和对细胞亡和细胞循环进展的影响.
主要方法:
- 合成pyrazol-4-yl-1,2,4-triazole-3-thiol衍生物 (14a-l),然后进行光谱表征 (例如NMR,质谱学).
- 使用MTT或类似方法进行体外抗增殖试验,以确定针对MCF-7,HT-29和A-549细胞系的IC50值.
- 对COX-2,野生型EGFR (EGFRWT) 和突变EGFR (EGFRT790M) 的酶抑制测定.
- 通过巴克斯和BCL-2蛋白质水平的西部斑点分析来评估亡诱导.
- 使用流细胞计进行细胞周期分析.
- 分子对接研究,以预测目标酶活性位点内的结合相互作用.
主要成果:
- 化合物14b,14g和14k表现出强大的抗增殖活性,IC50值在1.20-2.93μM之间对HT-29,MCF-7和A-549细胞系,在某些情况下表现优于标准药物.
- 这些活性衍生物显著抑制了COX-2 (IC50:0.560-4.692微米),EGFRWT (IC50:0.121-0.423微米) 和EGFRT790M (IC50:0.076-0.764微米).
- 化合物14b,14g和14k通过上调BAX和下调BCL-2来诱导亡. 化合物14g在MCF-7细胞中引起显著的G2/M阶段停止 (39.15%).
- 对接研究提供了关于COX-2,EGFRWT和EGFRT790M活性位点内的强效化合物的结合模式的见解.
结论:
- 合成的pyrazol-4-yl-1,2,4-triazole-3-thiol衍生物代表了一类有前途的抗癌剂.
- 化合物14b,14g和14k具有针对COX-2和EGFR的多重向抑制潜力,这使得它们成为进一步抗癌药物开发的有价值线索.
- 观察到的亡诱导和细胞循环停止机制支持它们的抗增殖作用.
更多相关视频
05:17Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...